Clinical evaluation study of newly developed Luminex-based all RAS mutation assay kit

ABSTRACT: Primary outcome(s): Concordance rate of both KRAS and NRAS gene exon 2, 3 and 4 mutations between standard genetic testings including sanger sequencing and an established in vitro diagnostic (IVD) kit for KRAS exon2, and a newly developed Luminex-based all RAS assay kit

DISEASE(S): Colorectal Cancer

PROVIDER: 2627147 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR